NAD+ for Sale USA: The Lot You Can Still Ask About

A listing offering NAD+ for sale USA is making three claims at once, and they are not equally checkable. One is about where a container is sitting. One is about who dispatches it. One is about where the material was made and tested, and that is the only one of the three that touches the material itself.

NAD+ is a coenzyme shipped by the gram, stable enough as a dry solid that the romance of cold-chain logistics does less work here than it would for a protein. What domestic supply genuinely buys is more prosaic and more useful: a jurisdiction, a return path, and a counterparty who can be asked which lot is in the box.

The domestic listing used as the worked example below:

What a NAD+ for sale USA listing is actually claiming

Separating the three claims takes one table and removes most of the ambiguity in this query. Each row states what the claim would have to mean to be true, and what a buyer can do to test it before paying.

The first two are logistics. Only the third says anything about what is in the container, and it is the one that listings state least often, because it is the one that requires a document rather than a sentence.

The repackager problem is a domestic problem

There is a comfortable assumption underneath most searches for domestic supply: that the risk being avoided lives abroad. For this compound that assumption is directly contradicted by the record.

In a notice whose content is current as of October 2024, FDA wrote that it is aware of compounders using food-grade nicotinamide adenine dinucleotide sold by repackagers to make intravenous products, and that ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins. It reported adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue, some requiring medical treatment, and stated these reactions are consistent with excessive levels of endotoxins.

Those compounders were American, the repackagers were selling into an American supply chain, and the people who received the products were in American clinics. Nothing in that sequence was fixed by proximity. The agency also urged manufacturers, including repackagers, to identify clearly on the label any ingredient intended for use in foods or dietary supplements, which is a direct statement that domestic containers were not declaring what they were.

So a domestic listing removes the customs question and leaves the grade question exactly where it was. The test that answers it is the bacterial endotoxins assay, and the argument for why it and not purity is set out in full on our injectable formats page.

The benchmark FDA already publishes

There is a useful standard sitting in plain sight, and it is worth borrowing even though it does not formally apply to research-use sales. Setting out the conditions for bulk substances used in compounding under section 503A, FDA states that bulk drug substances must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with the agency under section 510 of the Federal Food, Drug, and Cosmetic Act. The agency also urges compounders to know their bulks supplier.

Read that as two questions rather than one rule, because as two questions it transfers cleanly to a domestic listing.

• Is there a certificate of analysis, and is it valid for this lot rather than for a product line? A document with no lot number, no report date and no named laboratory fails on its face.
• Is the establishment that made the material identifiable at all? A domestic warehouse address is not a manufacturing registration, and a repackager is not a manufacturer. The distinction is exactly the one the 2024 notice was written about.

A research supplier is under no obligation to meet the 503A conditions, and this page does not pretend otherwise. The point is that the conditions describe what adequate provenance looks like when the material is destined for a sterile preparation, and a buyer is entitled to use that as the measuring stick regardless of which channel is selling.

What domestic dispatch is genuinely worth

Four things, and it is worth being precise about them because the marketing version is vaguer and larger.

• Transit time and handling. A dry solid in a sealed container is not fragile in the way a solution already made up in water is, so the gain here is about fewer days in uncontrolled conditions rather than a rescue from certain degradation. Storage after arrival matters more than the journey, and that is a question for the certificate and the label, not the courier.
• No import decision to survive. FDA publishes a personal importation page stating that in most circumstances it is illegal for individuals to import drugs or devices into the United States for personal use, alongside a narrow set of situations in which its personnel may consider a more permissive decision. Whether a particular research-use shipment engages that framing is fact-specific and not something to resolve from a product page. A domestic parcel does not raise the question.
• A return path that exists. A refund or replacement argument with a domestic entity is a different proposition from the same argument conducted across a border and a payment processor.
• Someone who can answer today. This is the one that turns into evidence. A seller holding stock can name the lot before dispatch and send the matching certificate; a seller who cannot is telling you the goods are not where the listing implies.

Why the clinic map varies by state and the substance does not

Readers comparing domestic options often find that availability looks different from one state to the next and conclude that the regulatory position differs too. It does not, and separating the two layers helps.

The federal layer concerns the substance. NAD+ has no marketing authorisation as an injectable drug, and the nicotinamide adenine dinucleotide entry sits in FDA's category 1 of substances nominated for use in compounding under section 503A, which is a statement of non-enforcement pending evaluation rather than approval. That position is the same in every state, and it is explained in full on our regulatory page.

The state layer concerns the provider. Compounding pharmacies are licensed by state boards of pharmacy, and their rules on office use, telehealth prescribing and administration differ. Outsourcing facilities are a separate category that registers with FDA and appears on a published list, which is a genuinely useful thing for a reader to know exists, because it means the question who compounded this has a checkable answer for one class of supplier.

So local variation is variation in who may provide a service, not evidence that the material is better somewhere. What a local provider is selling, and the questions worth asking at the desk, are covered in our local search page.

Verifying a domestic listing, in order

Five steps, arranged so that the ones which cost nothing come before the one that costs money.

1. Ask which lot number will ship, in writing, before ordering. An immediate answer is evidence of possession; a vague one is evidence about the supply chain.
2. Request the certificate for that lot, not a sample document. Check that the lot number, a named laboratory and a report date all appear on it.
3. Look for the bacterial endotoxins line and read its units. Purity and identity are the easy half of the document and are not the half that produced reported harm.
4. Read the returns and refund terms before paying, since the value of a domestic counterparty is realised only if there is a stated path.
5. On arrival, check the lot number on the container against the certificate you were sent. If they differ, the document you read describes different material.

The criteria behind step two and step three, applied to supplier selection generally, are in our sourcing checklist, and the channel-level comparison including overseas marketplaces is in where to buy NAD+. Pricing arithmetic, including the quantity tiers and the free-carriage threshold, is on our price page.

None of this establishes that infusing NAD+ achieves anything. The biochemistry of the coenzyme is well characterised; the clinical case is not, clinics market it well ahead of the evidence, and nothing on this page describes or implies human use.